fig1

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Figure 1. Flow chart of the study. NSCLC: Non-small cell lung cancer; ICIs: immune checkpoint inhibitors; EGFR: epidermal growth factor receptor.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/